Fig. 2
Comparison of treatment outcomes for those receiving BIC-, EVG-, RAL-, and DRV-based 3-drug regimens compared to those receiving DTG-based 3-drug regimen among A. ART-naïve and B. ART-experienced PWH. 1N represents the number of persons in each treatment group with complete information on variables used in the outcome model. 2Estimates and confidence intervals were calculated from inverse-probability weighted models, adjusted for age, sex, race and/or ethnicity, region, smoking, alcohol use disorder, drug use and dependence, homelessness, baseline low-density lipoprotein, baseline CD4 count, baseline VL, baseline VACS 2.0 index, and years on ART regimen for ART-experienced. 3Virologic non-response for ART-experienced was defined for individuals who were suppressed at baseline. DTG dolutegravir, BIC bictegravir, EVG elvitegravir, RAL raltegravir, DRV darunavir, PWH people with HIV, ART antiretroviral therapy, aOR adjusted odds ratio, CI confidence interval, VACS the Veterans Aging Cohort Study, CD4 clusters of differentiation 4, VL viral load